![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1350992
¼¼°èÀÇ Áø´Ü ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå(2023-2030³â)Global Artificial Intelligence (AI) in Diagnostics Market 2023-2030 |
¼¼°è AI Áø´Ü ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 23.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå È®´ë´Â ¼¼°è ÀÇ·áºñ Àý°¨¿¡ ÈûÀÔ¾î ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ AIÀÇ µµÀÔÀº »ó´çÇÑ ÀçÁ¤ Àý°¨¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ßÀº °ªºñ½Ñ Ä¡·áÀÇ Çʿ伺À» ÁÙÀ̰í Áúº´ÀÇ ÁøÇàÀ» ¸·À» ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¸°Ô AI ±â¼úÀ» µµÀÔÇϸé ÀÇ·áºñµµ Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ Ãß¼¼¿¡ µû¶ó ¾÷°è °ü°èÀÚµéÀº AI ±â¹Ý Áúº´ °¨Áö ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »õ·Î¿î Á¦Ç°À» Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù, ÀÌÁö½º¿Í ³ë½ºÀ£Àº °øµ¿À¸·Î AI ±â¹Ý Áúº´ °ËÃâÀ» À§ÇÑ ObtainÀ» 1,200¸¸ ´Þ·¯¿¡ Ãâ½ÃÇßÀ¸¸ç, ObtainÀº AscertainÀÇ ¾ÆÀ̵ð¾î·Î, AscertainÀ» µµÀÔÇÑ Ã¹ ¹øÂ° ±â¾÷À̱⵵ ÇÕ´Ï´Ù. Ascertain´Â ÀÌÁö½º º¥Ã³½º(Aegis Ventures)¿Í ³ë½ºÀ£ Ȧµù½º(Northwell Holdings)ÀÇ ÇÕÀÛ ÅõÀÚ·Î 2022³â ¹ÌÈ 1¾ï ´Þ·¯·Î Ãâ¹üÇÑ ±â¾÷ âÁ¶ Ç÷§ÆûÀÔ´Ï´Ù. ObtainÀº ȯÀÚÀÇ ´«ÀÇ À̹ÌÁö¸¸À¸·Î Áúº´ÀÇ Ãʱâ ¡Èĸ¦ ½Äº°ÇÏ´Â AI µµ±¸·Î, ÀÇ·á ¼ºñ½º Á¢±Ù¼ºÀ» °³¼±Çϰí ÀÇ·á ¼ºñ½ºÀÇ ÁúÀ» ³ôÀ̱â À§ÇØ AIÀÇ °¡´É¼º¿¡ µ¿ÂüÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
ÀÀ¿ë ºÐ¾ß Áß ½Å°æÇÐ ÇÏÀ§ ºÎ¹®Àº Áø´Ü ºÐ¾ß¿¡¼ ÀΰøÁö´É ¼¼°è ½ÃÀå¿¡¼ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å°æ°ú ÀÇ»ç´Â ³ú, ô¼ö ¹× ½Å°æ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´À» ½Äº°Çϰí Ä¡·áÇÏ´Â µ¥ ÁßÁ¡À» µÎ´Â ÀÇ»çÀÔ´Ï´Ù. ÀϹÝÀûÀÎ ½Å°æ°è Áúȯ°ú ³Ä¡¼º ½Å°æ°è ÁúȯÀ» ¸ðµÎ °í·ÁÇÏ¿© Áõ»óÀÇ ¿øÀÎÀ» ÆÄ¾ÇÇϰí Ä¡·á Àü·«À» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ½Å°æÇÐÀû °Ë»ç´Â ºûÀ̳ª ¹Ý»ç ¸ÁÄ¡¿Í °°Àº ±â±¸¸¦ »ç¿ëÇÏ¿© ½Å°æ°è¸¦ Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, AI ±â¹Ý µµ±¸´Â º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´Ü, ¸ÂÃãÇü Ä¡·á °èȹ, »õ·Î¿î Ä¡·á Á¢±Ù¹ý, È¿°úÀûÀÎ Áúº´ ¸ð´ÏÅ͸µÀ» ÅëÇØ ÀǷḦ º¯È½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. µû¶ó¼ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â º¸´Ù Á¤¹ÐÇϰí Á¤È®ÇÑ Áø´Ü ¹× °á°ú¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä Áõ°¡°¡ ÀÖ½À´Ï´Ù. ½Å°æ ¿µ»ó µ¥ÀÌÅÍ´Â AI ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© ºÐ¼®Çϸé Àΰ£ÀÇ ´«À¸·Î °£°úÇϱ⠽¬¿î ÀÌ»óÀ̳ª ÆÐÅÏÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ´õ ºü¸£°í Á¤È®ÇÑ Áø´ÜÀÌ °¡´ÉÇØÁ® ½ÃÀå °ü°èÀÚµéÀÌ ½Å°æ Áúȯ Áø´ÜÀ» À§ÇÑ AI ±â¹Ý ¼Ö·ç¼ÇÀ» °³¹ßÇϵµ·Ï ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù Å×¶ó·¹ÄÜ(TeraRecon)Àº AI ±â¹Ý ´º·Î ½ºÀ§Æ®(AI-Powered Neuro Suite)¸¦ Ãâ½ÃÇß½À´Ï´Ù. ¹æ»ç¼±»ç´Â Neuro Suite Ç÷§ÆûÀ» ÅëÇØ Combinostics, Imaging Biometrics, Cercare Medical°ú °°Àº ÃÖ°íÀÇ ½Å°æÇÐ °ø±Þ¾÷ü°¡ Á¦°øÇÏ´Â ´Ù¾çÇÑ AI ±â¹Ý ½Å°æ ¿µ»ó ¾ç½ÄÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ÀΰøÁö´É Áø´Ü ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹ ¹× ij³ª´Ù), À¯·´(¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, µ¶ÀÏ, ÇÁ¶û½º, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹, ÀϺ», Çѱ¹, ±âŸ ¾Æ½Ã¾Æ Áö¿ª), ±âŸ Áö¿ª(Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, Áß³²¹Ì) µî Áö¿ªº°·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù. ÀÌ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀº AI ±â¹Ý Áø´Ü ¼Ö·ç¼Ç »ç¿ëÀ» ÃËÁøÇϱâ À§ÇÑ °ø°ø ¹× ¹Î°£ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡·Î ÀÎÇØ ¼¼°è¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÅõÀÚ ¹× ÀÎ½Ä Áõ°¡¿Í ÇÔ²² ±â¾÷À̵éÀÇ °³Ã´ÀÌ ÀÌ Áö¿ª ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
¸ðµç Áö¿ª Áß ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀº ºÏ¹ÌÀÇ ¸¸¼º Áúȯ À¯º´·ü Áõ°¡¿Í ÀÇ·á ½Ã½ºÅÛ¿¡¼ ÷´Ü ±â¼úÀÇ ÅëÇÕÀÌ È®´ëµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. Áø´Ü¿¡ ÀÖ¾î AI´Â ¹æ´ëÇÑ ÀÇ·á µ¥ÀÌÅÍ ºÐ¼®À» Ž»öÇÒ ¼ö ÀÖ´Â ÀáÀçÀûÀÎ µµ±¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸¸¼º ÁúȯÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃã Ä¡·á¹ý °³¹ß·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå È®´ë¿¡ À¯¸®ÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù ¹Ì±¹ ¾Ï Çùȸ°¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¾à 190¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× Áß Àü¸³¼±¾ÏÀº 186,670°Ç, Æó¾ÏÀº 169,870°Ç, ¿©¼º À¯¹æ¾ÏÀº 144,490°Ç¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÑ Áø´Ü°ú Ä¡·áÀÇ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº Á¶±â Áø´ÜÀ» À§ÇÑ AI Ȱ¿ëÀ» ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Title: Global Artificial Intelligence (AI) in Diagnostics Market Size, Share & Trends Analysis Report by Type (Vitro Diagnostics, and Diagnostic Imaging), by Application (Cardiology, Oncology, Neurology, Obstetrics and Gynecology, and Others), and by End User (Hospitals, Diagnostics Imaging Centers, and Diagnostics Laboratories),Forecast Period (2023-2030).
The global AI in diagnostics market is anticipated to grow at a CAGR of 23. 5% during the forecast period (2023-2030). The expansion of the market is driven by the global reduction in healthcare expenses. The implementation of AI for early disease detection contributes to significant financial savings. As the early detection has the potential to reduce the necessity for expensive therapies and can hamper the progression of diseases. Medical costs can also be reduced by employing AI technology in that manner.
In line with this trend, industry stakeholders are introducing novel offerings to meet the growing demand for AI-based disease detection solutions. For instance, in May 2023, Aegis and Northwell collaboratively launched Obtain with $12 million for AI-powered disease detection. Obtain is the brainchild of Ascertain, which is also the first company to introduce Ascertain. Ascertain is a company creation platform that launched in 2022 with $100 million as a joint venture between Aegis Ventures and Northwell Holdings. Ascertains upcoming projects will revolve exclusively around joining the potential of AI to enhance healthcare accessibility and elevate the caliber of care provided. As far as Obtain is concerned, it is an AI tool which will identify initial indications of diseases solely through images of a patient's eye.
The global AI in diagnostics Market is segmented by type, application, and end-user. Based on type, the market is sub-segmented into in vitro diagnostics and diagnostic imaging. Based on the application, the market is sub-segmented into cardiology, oncology, neurology, obstetrics and gynecology, and others. Further, on the basis of end user, the market is sub-segmented into hospitals, diagnostic imaging centers, and diagnostic laboratories. Among the type segment, the in vitro diagnostics sub-segment is anticipated to hold a considerable share of the market owing to the fact that the medical and healthcare industries are increasingly utilizing AI solutions to reduce the potential for human errors and enhance treatment outcomes.
Among the applications, the neurology sub-segment is expected to hold a considerable share of the global artificial intelligence in diagnostics market. A neurologist is a physician who focuses on identifying and treating diseases affecting the brain, spinal cord, and nerves. Considering both common and difficult neurological diseases, they can assist in determining the cause of symptoms and developing a treatment strategy. Instruments, including lights and reflex hammers, can be used during a neurological exam to evaluate the nervous system. AI-based tools have the potential to transform health care, enabling faster and more accurate diagnosis, personalized treatment plans, new therapeutic approaches and effective disease monitoring. Thus, the primary factor supporting the market growth includes the increased demand for more precise and accurate diagnosis and results, globally. Neuroimaging data can be analyzed using AI algorithms to identify abnormalities and patterns that the human eye can overlook. This can result in earlier and more precise diagnoses, further propelling market players to develop AI-based solutions for diagnosing neurological disorders. For instance, in April 2023, TeraRecon launched the AI-Powered Neuro Suite. Radiologists can utilize a number of AI-powered neuroimaging modalities from top neurology suppliers, such as Combinostics, Imaging Biometrics, and Cercare Medical, using the Neuro Suite platform.
The global artificial intelligence in diagnostics market is further segmented based on geography, including North America (the US and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and the Rest of Asia), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased public and private initiatives to promote the use of AI-based diagnostic solutions. Additionally, the development of entrepreneurs along with the growing investment and awareness have promoted the expansion of the regional market.
Among all regions, North America is anticipated to grow at a considerable CAGR over the forecast period. The regional growth is attributed to the rising prevalence of chronic diseases within the country and the expanding integration of advanced technology in healthcare systems. AI in Diagnostics has emerged as a potential tool to navigate the analysis of extensive medical data, leading to the early detection of chronic diseases and the capacity to develop individualized treatments.
The increasing prevalence of chronic diseases across the region has created a favorable environment for market expansion. For instance, in January 2022, the American Cancer Society reports that the US is projected to witness the diagnosis of approximately 1.9 million new cancer cases. Out of which, prostate cancer cases are projected to reach 186,670, lung cancer cases to total 169,870, and female breast cancer cases to amount 144,490 in the upcoming year. Accurate diagnosis and treatment have grown more important as the prevalence of cancer and other chronic diseases rises. It is anticipated that such actions can promote the utilization of AI for early diagnosis, resulting in market growth.
The major companies serving the AI in diagnostics market include: Aidoc Medical Ltd., Digital Diagnostics Inc., IMAGEN, InformAI, LLC, Nano-x Imaging Ltd., and others. The market players are considerably contributing to market growth through the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2022, Indica Labs and The Industrial Centre for AI Research in Digital Diagnostics (iCAIRD) signed an agreement to collaborate on creating a digital pathology system powered by AI that can identify cancer in lymph nodes after colorectal surgery.